[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Institut du Cancer de Montpellier - Val d'Aurelle\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":621},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,50,0,25,[9,42,67,93,112,131,152,176,203,229,256,280,306,331,355,375,397,423,447,469,494,520,546,572,596],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100642071","effect-of-the-miroki-companion-robot-on-anxiety-in-pediatric-radiotherapy-100642071",false,"NCT07645950","Effect of the MIROKI Companion Robot on Anxiety in Pediatric Radiotherapy","KOKORO01","Inclusion Criteria:\n\n1. Children aged 4 to 18 years, distributed across the following age groups: 4-7 years, 8-12 years, and 13-18 years.\n2. Child with an indication for radiotherapy treatment at ICM.\n3. Child who speaks French.\n4. Child accompanied by a parent or legal guardian who agrees to participate in the study and provide consent.\n5. Child covered by the French national health insurance system.\n\nExclusion Criteria:\n\n6\\. Child with a diagnosed neurodevelopmental disorder as a comorbidity. 7. Child with postoperative cognitive sequelae that make interaction during care difficult (e.g., language impairment). 8. Total body irradiation. 9. Child under legal protection, unable to express assent, or presenting major difficulties in understanding the study information. Parent Inclusion Criteria\n\n1. Parent of a child enrolled in the study.\n2. Able to speak French.\n3. Willing to participate in the study. Parent Exclusion Criteria\n\n1\\. Parents or legal representatives under legal protection, or presenting an inability to consent or to understand the study information, making it impossible to provide free and informed consent for the minor's participation.",true,"ALL","4 Years",{"count":21,"type":22},6,"ESTIMATED","OBSERVATIONAL","Pediatric radiotherapy is an anxiety-provoking situation that can, on one hand, impair the child's cooperation and require sedation, and on the other hand,burden the care pathway by generating significant anxiety in both the child and their parents. Companion robots represent an innovative avenue for patient support, but they have never been evaluated in the context of radiotherapy. This study examines the effect of MIROKI, the first social robot capable of communication through a Large Multimodal Model (LMM), on children's state anxiety during radiotherapy. An experimental single-case design (SCED) will compare phases with and without the robot (withdrawal\u002Freversal), both in the waiting room and in the irradiation bunker. The primary outcome variable is anxiety, assessed in several ways: through questionnaires at the beginning and end of treatment; through an objective measure of cardiac activity (heart rate in bpm) during the radiotherapy session, with or without the MIROKI robot; and through an observational grid assessing the child's behavior. The intensive repeated measure (bpm) constitutes the preferred variable in this SCED design, while behavioral observation and anxiety questionnaires will support interpretation. The results could pave the way for reducing sedation and improving the overall care pathway in pediatric radiotherapy.",[26,27,28],"Pediatric Oncology","Radiotherapy","Parent","NOT_YET_RECRUITING","2026-06-09",{"date":32,"type":33},"2026-06-12","ACTUAL",{"date":35,"type":22},"2026-07",{"date":37,"type":22},"2027-07",{"name":39,"class":40},"Institut du Cancer de Montpellier - Val d'Aurelle","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":17,"sex":18,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100560308","using-the-epitranscriptome-to-diagnose-and-treat-gliomas-100560308","NCT06575452","Using the Epitranscriptome to Diagnose and Treat Gliomas","EPIGLIO","Inclusion Criteria:\n\n* Male \u002F female over 18 years of age,\n* Surgery (tumor resection) scheduled at Montpellier University Hospital for suspected, diffuse glioma, confirmed on tissue sample: IDH mutated grade 2 glioma (excluding tumors with a focus of grade 3 or 4 glioma), IDH mutated grade 3 glioma or GBM, IDH wild-type,\n* No history of treatment (surgery, radiotherapy or chemotherapy) for glioma,\n* Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures,\n* Patient has given express written informed consent prior to any study procedure,\n* Patient affiliated to a French health insurance.\n\nExclusion Criteria:\n\n* Patients whose regular follow-up is impossible for psychological, family, social or geographical reasons,\n* Patients under guardianship, curatorship or safeguard of justice,\n* Pregnant and\u002For breast-feeding patient (information gathered from the medical file, as part of the patient's standard medical care and follow-up),\n* Histo-molecular diagnosis of grade 4 IDH-mutated astrocytoma,\n* For grade 2 gliomas, presence within the tumor of one or more higher-grade sites (3 or 4).","18 Years",{"count":51,"type":22},228,"INTERVENTIONAL",[54],"NA","Diffuse gliomas are among the most common tumors of the central nervous system, with high morbidity and mortality and very limited therapeutic possibilities. The diffuse glioma are characterized by significant variability in terms of age at diagnosis, histological and molecular features, classification, ability to transform to a higher grade and\u002For to disseminate in the brain, response to treatment and patient outcome.\n\nOne of the main challenges in the management of diffuse gliomas is related to tumor heterogeneity within the same subgroup. Establishing an accurate tumor classification is of paramount importance for selecting personalized therapy or avoiding unnecessary treatment.\n\nAt present, the main diagnostic methods for detecting gliomas are based on histopathological features and mutation detection. Yet difficulties remain, due to tumor heterogeneity and sampling bias for tumors obtained from small biopsies. In particular, grade 2 (low-grade) and grade 3 (high-grade) gliomas cannot be easily distinguished, as intra-tumoral tumor grade heterogeneity is not uncommon in patients treated with extensive surgical resection. Another challenge in the field of gliomas is longitudinal monitoring of disease progression, which is currently mainly based on repeated brain Magnetic Resonance Imaging (MRI). New tools to detect tumor changes before the onset of imaging changes would be useful.\n\nSeveral genetic, epigenetic, metabolic and immunological profiles have been established for gliomas. Recently, the world of RiboNucleic Acid (RNA) has emerged as a promising area to explore for cancer therapy, especially since the (re)discovery of RNA chemical modifications. To date, more than 150 types of post-transcriptional modifications have been reported on various RNA molecules. This complex landscape of chemical marks embodies a new, invisible code that governs the post-transcriptional fate of RNA: stability, splicing, storage, translation.",[57],"Glioma","RECRUITING",{"date":60,"type":33},"2026-06-11",{"date":62,"type":33},"2026-06-01",{"date":64,"type":22},"2031-05",{"name":39,"class":40},2,{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":75,"minAge":49,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":52,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":66},"100625086","evaluation-of-the-impact-of-pre-habilitation-using-physiotherapy-and-mechanical-stimulation-on-shoulder-pain-and-mobility-in-patients-undergoing-breast-reconstruction-using-a-latissimus-dorsi-flap-100625086","NCT07418060","Evaluation of the Impact of Pre-habilitation Using Physiotherapy and Mechanical Stimulation on Shoulder Pain and Mobility in Patients Undergoing Breast Reconstruction Using a Latissimus Dorsi Flap","Randomized, Multicentre Study Evaluating the Impact of Pre-habilitation Using Physiotherapy and Mechanical Stimulation on Shoulder Pain and Mobility in Patients Undergoing Breast Reconstruction Using a Latissimus Dorsi Flap","PREHAB KINELGD","Inclusion Criteria:\n\n* Female patient aged 18 years or older\n* Scheduled for breast reconstruction with a latissimus dorsi flap following breast cancer\n* Patient has been informed and has signed the informed consent form\n* Affiliated with a social security system\n\nExclusion Criteria:\n\n* Patient with pre-existing shoulder pathology (Constant score \\\u003C 80\u002F100)\n* Patient with uncontrolled psychiatric or mental disorders\n* Patient unable to understand French","FEMALE",{"count":77,"type":22},72,[54],"Each year in France, nearly 59,000 new cases of breast cancer are diagnosed, and approximately 22,000 mastectomies are performed. Among these patients, 30% choose to undergo breast reconstruction. Breast cancer leads to numerous physical and psychological changes. The need to strengthen patient support around breast reconstruction has been highlighted, and it is one of the priorities of the national Ten-Year Cancer Control Strategy. The growing number of patients living after cancer makes the management of post-treatment sequelae essential.\n\nThe rate of reconstruction is increasing thanks to improvements in technique and better access to information. Among the available options, the latissimus dorsi (LD) flap has been a standard technique for immediate and delayed breast reconstruction for over 25 years. The LD technique offers several advantages: high reliability, feasibility even in irradiated thoraxes, low rates of postoperative complications, and satisfactory aesthetic outcomes. Its versatility and reliability have made it a cornerstone of breast surgery. However, this technique can lead to short- and long-term functional sequelae, which persist in 10% of patients. To reduce these side effects, an optimized version-the lipofilled mini-latissimus dorsi flap (mLD)-was developed by a team in Strasbourg. This quicker and less muscle-invasive technique is mainly used for immediate reconstruction or to replace implant-based reconstruction, with systematic lipofilling. However, no objective functional assessment of this method has yet been carried out, justifying a stratification according to the type of procedure for randomization in future studies. According to a prospective Icelandic study involving 15 patients, full recovery can be expected, but patients must be informed of the time and effort required to achieve it. The authors also concluded that further research is necessary to better understand the limits of long-term recovery.\n\nA study of 450 LD reconstructions showed that pain and the main functional sequelae were located in the back and shoulder, with 10% of patients experiencing significant long-term pain. In addition, according to this study, around 40% of patients consider postoperative sequelae and scarring burdensome. However, regret rates remain low, at under 3%.\n\nIn view of these findings, preventing pain and functional impairment has become a key research focus to improve patients' quality of life.\n\nPostoperative rehabilitation plays a crucial role in managing pain, reducing functional impairment, and optimizing aesthetic outcomes. The addition of mechanostimulation (MS) has been shown to improve scar appearance, shoulder function, and functional well-being compared with rehabilitation alone. MS is delivered using a device equipped with motorized rollers and suction to mobilize tissues. In physiotherapy, it helps relieve pain and improve mobility.\n\nPrehabilitation, a rapidly expanding concept in surgery, aims to prepare patients before their procedure. However, to date, no prehabilitation approach combining physiotherapy and MS has been considered prior to LD flap surgery. One study highlighted improved tissue trophicity after tissue preparation with MS before lipomodelling.\n\nThe objective of our study is to evaluate the benefit of prehabilitation through physiotherapy incorporating MS to prepare tissues (in particular skin and muscle) on shoulder pain and functional outcomes in patients undergoing breast reconstruction with a latissimus dorsi flap.\n\nAdditionally, due to the heterogeneity and sometimes limited access to specialized postoperative physiotherapy, extensive patient follow-up has been planned in order to describe, on an exploratory basis, real-world rehabilitation practices.",[81,82,83,84],"Breast Cancer","Physiotherapy","Breast Reconstruction","Latissimus Dorsi Flap","2026-06-02",{"date":87,"type":33},"2026-06-04",{"date":89,"type":22},"2026-08",{"date":91,"type":22},"2029-05",{"name":39,"class":40},{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":18,"minAge":49,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":109,"leadSponsor":111,"locationsCount":41},"100624022","multidimensional-study-designed-to-develop-a-methodological-framework-based-on-mri-data-to-predict-pathological-complete-response-pcr-in-patients-with-locally-advanced-rectal-cancer-after-neoadjuvant-treatment-100624022","NCT07404228","Multidimensional Study Designed to Develop a Methodological Framework Based on MRI Data to Predict Pathological Complete Response (pCR) in Patients With Locally Advanced Rectal Cancer After Neoadjuvant Treatment","RESTAGE","Inclusion Criteria for the preclinical phase :\n\n* Age ≥18 years old;\n* Have a confirmed diagnosis of locally advanced rectal cancer;\n* Have completed neoadjuvant chemoradiotherapy;\n* Be a candidate for surgical treatment with total mesorectal excision;\n* Be willing and able to provide written informed consent;\n* Affiliation to the French Social Security System.\n\nInclusion criteria for the clinical phase:\n\n* Age ≥18 years old;\n* Have a confirmed diagnosis of locally advanced rectal cancer;\n* Require neoadjuvant chemoradiotherapy or have completed neoadjuvant chemoradiotherapy;\n* Requires either surgical treatment or a non-surgical strategy (\"Watch-and-Wait\") after neoadjuvant chemoradiotherapy;\n* Be willing and able to provide written informed consent;\n* Affiliation to the French Social Security System.",{"count":101,"type":22},115,"Rectal cancer presents a significant global health challenge. Despite improvements in clinical outcomes, significant disparities persist across Europe. These differences are explained not only by the heterogeneity of risk factors and screening strategies, but also by variations in diagnostic and therapeutic approaches, which are highly dependent on medical imaging.\n\nStandard treatment for locally advanced rectal cancer based on staging MRI is neoadjuvant treatment (NAT), for tumour downsizing and downstaging, followed by total mesorectal excision. In a significant proportion of cases, radical surgery leads to substantial long-term complications like sexual and urinary dysfunction, fecal incontinence, and impairment in daily activities. Given that up to 42% of patients show complete tumor regression at pathology (i.e. pathological complete response pCR), to avoid unnecessary radical surgery, non-operative management has become an attractive alternative when there are no signs of viable tumour after NAT (i.e. clinical complete response cCR). Such patients are candidates for Watch-and-Wait (W\\&W), an established active surveillance policy in specialized centers worldwide relying on clinical examination, endoscopy and MRI.\n\nOn the other hand, W\\&W carries a risk of local regrowth (persistence of microscopic residual disease despite apparent cCR). Even in expert hands, assessment of tumor response is not perfect and local regrowth based on current selection methods occurs in \\~30% of cases. Although deferred surgery is a successful treatment with no apparent negative impact on local disease control, an increased rate of distant metastases has been recently reported.\n\nTherefore, there is a critical unmet clinical need to detect complete responses after NAT and avoid unnecessary surgery with its associated morbidity and quality of life impairment risks, while also improving sensitivity for residual microscopic disease that will result in local regrowth and associated reduced disease-free survival.\n\nRectal cancer poses a burden not only on healthcare systems, but also on patient well-being. Patients frequently suffer from feelings of isolation and helplessness when faced with unpredicted disease-related situations, given the common difficulties to access high quality information and communicate with attending physicians. As such, there is a clear need to unburden healthcare facilities from unnecessary hospital visits, while improving patient outcomes, engagement, support and care.",[104,105,106],"Rectal Cancer","Chemoradiotherapy","Mri",{"date":87,"type":33},{"date":89,"type":22},{"date":110,"type":22},"2029-11",{"name":39,"class":40},{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":18,"minAge":49,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":52,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":41},"100600491","contribution-of-preserving-the-superior-left-colic-artery-to-the-vascularization-of-the-descending-colon-prior-to-colorectal-anastomosis-during-left-sided-or-rectal-resections-for-colorectal-or-ovarian-cancer-revascularisation-colique-100600491","NCT07098182","Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique)","Clinical Study Evaluating the Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique)","Inclusion Criteria:\n\n* Male\u002F female aged over 18 years,\n* Histologically proven left colon or rectal adenocarcinoma OR ovarian carcinoma (with potential colorectal resection),\n* Scheduled surgery for left colic or rectal carcinoma\u002F\u002F Scheduled surgery for ovarian carcinoma with potential colorectal resection,\n* Surgical indication of colo-rectal resection validated in RCP and confirmed during the operative exploration (ovarian cancer,\n* WHO Status \\\u003C 3\n* Patient who has given informed, written and express consent,\n* Patient (s) affiliated to a French social security.\n\nExclusion Criteria:\n\n* Contraindication to indocyanine green: thyroid adenoma, hyperthyroidism, hypersensitivity or allergy to one of the components, severe renal failure (GFR \\\u003C30 ml\u002Fmin\u002F1.73m2),\n* Patient with a history of abdominal vascular surgery\n* Patient (e) not having left colic artery on vascular mapping of preoperative abdominal-pelvic scanners,\n* Patient whose regular follow-up is not possible for psychological, family, social or geographical reasons,\n* Patient (s) under guardianship, curatorship or safeguard of justice,\n* Pregnant and\u002For breastfeeding patient,",{"count":5,"type":22},[54],"Colorectal cancers and ovarian cancers are respectively the 2nd and 5th cause of cancer mortality in France.\n\nSurgical resection is a crucial step in the therapeutic management of colorectal cancers. For advanced ovarian cancers, the objective of cytoreductive surgery is to obtain complete macroscopic resection with no visible residual disease. One or more digestive resections are often required to achieve this goal of complete surgery (usually a modified posterior pelvic exenteration with colorectal resection).\n\nA ligation of the inferior mesenteric artery at its origin is classically performed in left colectomies and rectal resection for colorectal cancers. This allows the resection of the colorectal segment with a complete mesocolic lymphadenectomy until the origin of the inferior mesenteric artery and a good mobilization of the descending colon to allow its anastomosis to the underlying rectal stump. This ligation of the inferior mesenteric artery at its origin is also frequently performed in cases of modified posterior pelvic exenteration for ovarian cancer.\n\nRecently, several studies suggest that arterial ligation of the inferior mesenteric artery could be performed below the emergence of the left colic artery. Its preservation requiring a meticulous vascular dissection would allow a better vascularization of the descending colon and of the colorectal anastomosis without affecting the carcinologic quality of the resection and the number of resected lymph-nodes. Indeed, the most feared complication during colorectal anastomosis is the anastomotic leakage whose rates are on average 15% in rectal cancer with low anastomosis and 6% in ovarian cancers.\n\nVerifying the adequate vascularization of the descending colon before performing the colorectal anastomosis is a crucial step in reducing the risk of postoperative fistula. However, quantifying this vascularization is challenging, and several techniques can be used to assess it. The gold standard technique involves measuring arterial pressure using a catheter inserted into the marginal artery of the descending colon. Other non-invasive techniques also use Doppler studies to calculate pressure in the marginal artery or assess oxygen saturation using a sterile sensor.\n\nStudies have shown that the use of indocyanine green in colorectal surgery, particularly to evaluate perfusion before the creation of an anastomosis, significantly reduces the rate of anastomotic leakage. Indocyanine green is a fluorescent dye that, after intravenous injection, binds to plasma proteins and allows tissue perfusion to be visualized using a fluorescence system.\n\nThe objective of this project is to show that the preservation of the left colic artery is possible and allows a better vascularization of the descending colon before colorectal anastomosis.",[104,123,124],"Colon Cancer","Ovarian Cancer",{"date":87,"type":33},{"date":127,"type":33},"2025-11-27",{"date":129,"type":22},"2026-10",{"name":39,"class":40},{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":18,"minAge":49,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":52,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":41},"100580237","evaluating-laser-photobiomodulation-for-the-treatment-of-neuropathic-pain-in-chemotherapy-induced-peripheral-neuropathy-in-cancer-patients-100580237","NCT06834685","Evaluating Laser Photobiomodulation for the Treatment of Neuropathic Pain in Chemotherapy-induced Peripheral Neuropathy in Cancer Patients","Evaluating Laser Photobiomodulation for the Treatment of Neuropathic Pain in Chemotherapy-induced Peripheral Neuropathy: a Randomized, Non-comparative, Placebo-controlled, Single-blinded, Phase II Clinical Trial in Cancer Patients","NEUROdoux","Inclusion Criteria:\n\n* Male or female aged 18 years minimum;\n* Patient treated at the Montpellier Cancer Institute for a cancer (whatever the location) requiring a chemotherapy;\n* Patient with significant NP defined as a score of 4 at the clinician-rated DN4 ;\n* Patient with a NP for at least 3 months after the end of an adjuvant or neo-adjuvant chemotherapy;\n* Women of childbearing potential must have a pregnancy urinary test within a maximum of 7 days before starting the study treatment. A negative result must be documented before study treatment is started. Women without reproductive potential are postmenopausal women or women who have undergone permanent sterilisation (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy);\n* Effective contraception for women of childbearing age\n* Patient having signed informed consent prior to any study procedure;\n* Patient affiliated to a French social protection system;\n* Patient sufficiently fluent in French to complete questionnaires, as the investigator clinical discretion.\n\nExclusion Criteria:\n\n* Patient unable to come twice a week to the Montpellier Cancer Institute;\n* Patient unable to sit for a 30-minutes period;\n* Patient with an open wound or ulcer on the treatment area;\n* Patient whose diagnosis of peripheral neuropathy is due to another cause (n.b., diabetes without neuropathy will not be a specific exclusion);\n* Patient with uncontrolled psychiatric illness or neurocognitive impairment that may interfere with assessments, as the investigator clinical discretion;\n* Patient whose estimated life expectancy is less than 3 months, as estimated by a clinical investigator;\n* Patient using another concurrent non-pharmacological intervention or complementary therapy for neuropathy during the study;\n* Patient who has been treated with CAPSAISINE during the previous 3 months;\n* Patient with pacemaker;\n* Epileptic patient;\n* Patient with photosensitive medications, or any medical condition causing sensitivity to light (n.b., Lupus);\n* Pregnant and\u002For breastfeeding woman;\n* Patient with primary tumor and\u002For metastases in areas to be treated by BPM (i.e., hands and\u002For feet);\n* Patient with pre-existing eye disease (such as maculopathy, glaucoma, cataract and retinal lesions), or a history of family eye diseases;\n* Patient who has been already been treated with photobiomodulation on the area of interest.\n* Participation in another concomitant clinical study with neuropathic pain or chemo-induced peripheral neuropathy as the primary endpoint.\n* Presence of a tattoo on the area to be treated.",{"count":140,"type":22},70,[54],"Chemotherapy-induced peripheral neuropathy (CIPN) (including taxanes, platinum, al pervenche from Madagascar alkaloids...), is a frequent secondary effect of treatments: 68% at 1-month post-chemotherapy, 60% at 3 months and 30% after 6 months. Symptoms associated with CIPN are usually symmetric and bilateral (typical distribution in \"gloves and socks\") inducing sensory alterations, paresthesias, dysesthesias, numbness and pain. Neuropathic Pain (NP) is an important characteristic of CIPN, affects 25-80% of patients with CIPN, and reduces quality of life (e.g., concomitant psychological distress, risks of falls, risks of neurocognitive impairments, and sleep disorders).\n\nIn severe cases, it is even necessary to delay and\u002For reduce the dose of chemotherapy. The benefit of drug interventions on NP remains limited. To date, there are no proven preventive strategies and few evidence-based treatment options for CIPN. Also, the use of complementary or non-pharmacological interventions are common, including photobiomodulation (PBM).\n\nPBM is the therapeutic use of non-ionizing laser light for its anti-inflammatory and regenerative effects. Its use is currently recommended only for the prevention of oral mucositis related to cancer treatments. Recent preliminary clinical evidence suggests that PBM may be beneficial to established CIPN, with safety and improvement beyond the intervention. However, to date, clinical trials are rare, have methodological weaknesses, and\u002For focus on global CIPN. The overall objectives of the study are therefore to assess the effectiveness, feasibility and safety of the PBM for treating NP in the CIPN.",[144,145],"Cancer Survivors","Peripheral Neuropathic Pain",{"date":87,"type":33},{"date":148,"type":33},"2025-10-07",{"date":150,"type":22},"2028-12",{"name":39,"class":40},{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":18,"minAge":49,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":52,"phases":162,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":175},"100435791","phase-2-assessment-of-retreatment-with-lutathera-in-patients-with-new-progression-of-intestinal-well-differenciated-net-100435791","NCT04954820","Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET","A Prospective Randomized Phase II Study Assess the Schema of Retreatment With Lutathera® ([177LU]LU-DOTA-TATE) in Patients With New Progression of Intestinal Well-differenciated Neuroendocrine Tumor","ReLUTH","Inclusion Criteria:\n\n* Age ≥ 18 years,\n* Histologically proven intestinal G1 or G2 neuroendocrine tumors (NET),\n* Patient previously treated with 4 cycles of Lutathera® (defined as \"First PRRT\"),\n* Disease control after \"First PRRT\" ≥ 12 months,\n* Patient presenting a progression of disease (clinic, biologic and\u002For radiologic) after a first PRRT,\n* Decision of retreatment with Lutathera® (defined as \"Second PRRT\") validated by RENATEN and\u002For multidisciplinary tumor board and in the scope of the French reimbursement process,\n* ECOG performance status 0-2,\n* Life expectancy ≥ 6 months as prognosticated by the physician,\n* Somatostatin receptor imaging positive imaging (SSTRi+) disease within 4 months prior to inclusion : (may be PET imaging (68Ga-based SSTR analogues) or scintigraphy imaging: 111In-pentetreotide or 99mTc-octreotide. At least 90% of lesions must be positive for SSTRi with a significant uptake (\\>= liver of surrounding tissue),\n* Measurable disease per RECIST 1.1 (Appendix 1), on CT\u002FMRI scans, defined as at least 1 lesion with ≥ 1 cm in longest diameter, and ≥ 2 radiological tumors lesions in total,\n* Adequate bone marrow reserve (Hb \\> 8 g\u002Fdl, neutrophils ≥ 1500\u002Fmm³ and platelets ≥ 80 000\u002Fmm³),\n* Negative pregnancy test in women of childbearing potential (the β-HCG dosage must be ≤ 4 days before inclusion). Women who have no reproductive potential are postmenopausal women or women who have had permanent sterilization, eg. tubal occlusion, hysterectomy, bilateral salpingectomy),\n* Effective contraception in men or women of childbearing or pre-menopausal age and up to a minimum of 6 months following the end of treatment,\n* Patient´s signed written informed consent,\n* Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures,\n* Affiliation to the French Social Security System\n\nExclusion Criteria:\n\n* Patient who did not respond (no CR, PR or SD) to \"first PRRT\".\n* Radiological progression after two cycles of \"Second PRRT\" according to RECIST version 1.1,\n* Grade 4 hematotoxicity and\u002For nephrotoxicity during the initial PRRT, or unresolved AEs categorized as Grade 2 or higher (as per Common Terminology Criteria for Adverse Events (CTCAE v5.0) from previous PRRT cycles or any other therapy for NET, excluding alopecia and peripheral neuropathy,\n* Pancreatic NET,\n* NeuroEndocrine Carcinoma,\n* Prior external beam radiation therapy to more than 25% of the bone marrow,\n* Severe renal (estimated Glomerular Filtration Rate (GFR) according to Modification of Diet in Renal Disease (MDRD) \\\u003C 40 mL\u002Fmin or nephrotic syndrome) or hepatic insufficiency (Alanine aminotransferase (ALT)\u002F aspartate aminotransferase (AST) \\> 2.5 x ULN or ALT\u002FAST \\> 5 x ULN if liver function abnormalities are due to the underlying malignancy and\u002For total serum bilirubin \\> 2.5 x ULN),\n* Serum albumin \\\u003C 3.0 g\u002FdL unless prothrombin time is within the normal range,\n* Uncontrolled diabetes mellitus as defined by a fasting blood glucose above 2 ULN,\n* Uncontrolled decompensated heart failure, myocardial infarction uncontrolled, stroke, pulmonary embolism or revascularization procedure, unstable angina pectoris, uncontrolled cardiac arrhythmia, and clinically significant bradycardia during the last 12 months,\n* Hypertension that cannot be controlled despite medications (≥ 160\u002F95 mmHg despite optimal medical therapy)\n* Brain metastases (unless these metastases have been treated and stabilized for at least 24 weeks, prior to enrolment in the study. Patients with a history of brain metastases must have a head CT scan with contrast or MRI to document stable disease prior to enrolment in the study),\n* Pregnancy or breast feeding,\n* Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results,\n* Known hypersensitivity to any of the study drugs, study drug classes, or any constituent of the products,\n* Concomitant participation or participation within the last 30 days in another clinical trial,\n* History of other solid tumor in 5 years before the inclusion excepted of cancer in situ of the cervix and skin cancer (basal or squamous cell) treated and controlled.\n* Legal incapacity or physical, psychological or mental status interfering with the patient's ability to sign the informed consent or to terminate the study.",{"count":161,"type":22},146,[163],"PHASE2","In France, since the reimbursement of Lutathera®, this treatment is allowed for retreatment if patients still fulfill the criteria of its indication and 4 news cycles could be proposed. However, clinical practices are heterogeneous regarding the number of new cycles and most teams perform only two additional cycles (every 8 weeks). Therefore, the coordinator propose to evaluate the efficacy of two additional cycle of Lutathera® versus active surveillance in patients already retreated with two cycles Lutathera® for a new progression of intestinal neuroendocrine tumor and who previously received the 4 cycles of treatment with a clinical benefit.",[166,167,168],"Neuroendocrine Tumors","Intestinal Well Differentiated Endocrine Tumor","Progressive Disease",{"date":87,"type":33},{"date":171,"type":33},"2021-10-18",{"date":173,"type":22},"2033-10",{"name":39,"class":40},28,{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":75,"minAge":49,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":52,"phases":187,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":196,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":202},"100397651","evaluation-of-the-efficacy-of-a-physical-therapy-yoga-patient-educational-program-for-breast-cancer-patients-with-pain-due-to-hormonal-therapy-treatment-100397651","NCT04457895","Evaluation of the Efficacy of a Physical Therapy-yoga-patient Educational Program for Breast Cancer Patients With Pain Due to Hormonal Therapy Treatment.","A Randomized, Open-labelled, Controlled Trial Evaluating the Efficacy of a Physical Therapy-yoga-patient Educational Program for Breast Cancer Patients With Pain Due to Hormonal Therapy Treatment.","SKYPE2","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Non metastatic breast cancer\n* Ongoing hormone therapy, with no treatment modification in the 30 days before inclusion\n* Osteoarticular and\u002For musculoskeletal pain due to HT ≥ 4 on the Numeric Pain Rating Scale (NPRS)\n* Previous treatment (surgery, chemotherapy or radiotherapy) ended at least 2 months before inclusion\n* Informed patient and signed informed consent received\n* Affiliation to a social security system\n\nExclusion Criteria:\n\n* Chronic rhumatologic pain with specific care needed\n* Regular Yoga practice in the 3 months before inclusion\n* Contraindication or clinical state not allowing physical practice\n* Patient whose regular follow-up is initially impossible for psychological, family, social or geographical reasons,\n* Pregnant and breastfeeding woman","99 Years",{"count":186,"type":22},108,[54],"As much as 50% of patients treated with hormonotherapy (HT) for breast cancer (BC) suffer from osteoarticular pain during treatment. Secondary effects have become a real issue because of their consequences on the patients' quality of life, but also on treatment efficacy and survival when they induce dose reduction or premature withdrawal of treatment.\n\nAdditional medicines (acupuncture, hypnosis, yoga) have become more and more popular these last years. 48 to 80% of patients with BC eventually choose them. A review comparing efficacy of various therapies to decrease osteoarticular pain concludes to a highest efficacy of anti-inflammatory treatments, paracetamol and yoga.\n\nIt thus appears innovative to complete this care with a patient educational project (PEP) in postural yoga instructed by a trained physical therapist, which will enable patients to practice yoga postures at home by themselves.\n\nThe investigators conducted a pilot study \"SKYPE\" with 24 algic patients treated with HT after BC, whose results are very promising.\n\nThe investigators now propose in the continuity of the pilot study a multicenter randomized controlled study comparing the efficacy of SKYPE care on pain reduction, an educative care combining physical therapy and yoga, to a control group in patients treated with HT for a BC with osteoarticular and\u002For musculoskeletal pain.\n\nFurthermore, in order to examine whether yoga interventions may influence inflammation through their effects on the level of a wide range of pro- and anti-inflammatory cytokines (30), the investigators will Change in circulating cytokines' level between baseline level (T0) and post-treatment level (T2) in both groups will be analyzed and if so correlation will be established.",[81],[191,192,193,194,195],"breast cancer","hormonotherapy","osteo articular pain","yoga","patient educational project",{"date":87,"type":33},{"date":198,"type":33},"2021-02-11",{"date":200,"type":22},"2028-08",{"name":39,"class":40},7,{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":12,"sex":18,"minAge":49,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":52,"phases":213,"briefSummary":214,"conditions":215,"keywords":218,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":227,"locationsCount":228},"100370529","clinico-biological-database-in-patients-treated-with-metabolic-radiotherapy-in-the-nuclear-medicine-department-100370529","NCT04104529","Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department","Establishment of a Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department","BCB RIV","Inclusion Criteria:\n\n* Age ≥ at 18 years old,\n* Patient treated in the Nuclear Medicine Department for the treatment by metabolic radiotherapy,\n* Patient treated as part of his treatment for:\n\n  * thyroid cancer,\n  * a neuroendocrine tumor or\n  * prostate cancer.\n* Patient having accepted the complementary blood sample,\n* Patient having given his informed, written and express consent.\n\nExclusion Criteria:\n\n* Patient not affiliated to a social security scheme,\n* Subject under tutelage, curatorship or safeguard of justice,\n* Patient in an emergency situation\n* Patient whose regular monitoring is a priori impossible for psychological, family, social or geographical reasons,\n* Pregnant and \u002F or breastfeeding woman",{"count":212,"type":22},350,[54],"Development of a clinico-biological database allowing the provision of clinical data and corresponding biological materials to the medical and scientific community.",[216,217,166],"Thyroid Cancer","Prostate Cancer",[219,220,221,222],"thyroid cancer","prostate cancer","neuroendocrine tumors","nuclear medecine",{"date":87,"type":33},{"date":225,"type":33},"2019-10-28",{"date":129,"type":22},{"name":39,"class":40},4,{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":18,"minAge":49,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":52,"phases":240,"briefSummary":241,"conditions":242,"keywords":244,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":255},"100444313","phase-2-efficacy-of-gembrax-followed-by-folfirinox-versus-folfirinox-alone-in-first-metastatic-line-pancreatic-cancer-patients-100444313","NCT05065801","Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients","Randomized Phase II Trial Evaluating the Efficacy of a Sequential Treatment Gemcitabine Plus Nab-paclitaxel (Gembrax) Followed by Folfirinox Versus Folfirinox Alone in Patients Treated in First Metastatic Line Pancreatic Cancer","GABRINOX2","Inclusion Criteria:\n\n1. Male or female aged 18 to 75 on the date the consent is signed.\n2. Histologically or cytologically proven metastatic pancreatic adenocarcinoma. The definitive diagnosis of pancreatic adenocarcinoma metastases will be made by integrating the histopathological data in the context of the radiological data.\n3. One or more metastatic lesion (s) measurable (Recist 1.1) by Thoraco-Abdomino-Pelvic scanner (or hepatic MRI and Thoraco-Abdomino-Pelvic scanner not injected, if the patient is allergic to the product of contrast).\n4. Previous treatment (including radiochemotherapy) for the non-metastatic disease authorized if a delay ≥ 6 months between the last treatment and the recurrence is respected.\n5. WHO performance status ≤ 1\n6. Uracilemia \\\u003C16 ng \u002F ml\n7. Acceptable hematological assessment at inclusion (obtained within 14 days before the start of treatment) defined by: • Neutrophils ≥ 2 × 109 \u002F L; • Platelets ≥ 100,000 \u002F mm3 (100 × 109 \u002F L); • Hemoglobin ≥ 9 g \u002F dl.\n8. Acceptable renal and hepatic function at inclusion (obtained within 14 days before the start of treatment) defined by: • AST and ALT ≤ 2.5 x upper limit of the norm (ULN), unless liver metastases are present in this case AST and ALT ≤ 5 × ULN is allowed; • Total bilirubin ≤ 1.5 x ULN; • Serum creatinine within the norm limits or calculated clearance ≥ 50ml \u002F min for patients with a serum creatinine value above or below the norm values (clearance calculated by the CKD-EPI formula).\n9. Calcemia AND magnesemia AND kalaemia ≥ LLN and ≤ 1.2 x ULN\n10. If the patient is sexually active, he must agree to use contraception deemed adequate and appropriate by the investigator throughout the period of administration of the study drug and up to 6 months after discontinuation of treatment for women and for men.\n11. Signature of consent before any procedure specific to the study.\n12. Affiliated with the French national social security.\n\nExclusion Criteria:\n\n1. Known brain metastasis.\n2. Previous treatment with radiotherapy, surgery, chemotherapy or experimental therapy for the treatment of metastatic disease.\n3. Major surgery, other than diagnostic surgery (that is, surgery done to obtain a diagnostic biopsy without organ harvesting), within 4 weeks of day 1 of study treatment.\n4. Known Gilbert's syndrome or homozygous for know UGT1A1 \\* 28\n5. Other concomitant cancer or history of cancer, except cervical cancer in situ treated, skin basal or squamous cell carcinoma, superficial bladder tumor (Ta, Tis, and T1) or a tumor with a good prognosis treated curatively without chemotherapy and without any sign of disease in the 3 years preceding inclusion.\n6. Patients with high cardiovascular risk, including, but not limited to, coronary stent or myocardial infarction within the past 6 months.\n7. Peripheral sensory neuropathy ≥ grade 2 at the time of inclusion.\n8. ECG with a QTc interval greater than 450 ms for men and greater than 470 ms for women\n9. Any other concomitant and unbalanced disease or serious disturbance that may interfere with the patient's participation in the study and his safety during the study (eg severe hepatic, renal, pulmonary, metabolic, or psychiatric disorders)\n10. Allergy or intolerance to any study drug (gemcitabine, nab-paclitaxel, oxaliplatin, irinotecan, 5-FU) or any excipient (e.g., fructose) as described in the sections \" contraindication or special warnings and precautions\" or \"prescribing information\" of the summary of product characteristics indications.\n11. Pregnant or breastfeeding women. Women of childbearing potential must have a negative pregnancy test (serum β-hCG) within 72 hours prior to inclusion.\n12. Patients on vitamin K antagonists (e.g., Coumadin) (modifications to treatment may be required prior to inclusion).\n13. Treatment with brivudine within 4 weeks before or after treatment with 5-fluorouracil (due to a potentially fatal interaction).\n14. Active and uncontrolled bacterial, viral, or fungal infections requiring systemic treatment.\n15. Active HIV infection, known hepatitis B or C infection.\n16. History of peripheral arterial disease (e.g., claudication, Buerger's disease), chronic inflammatory bowel disease or rectal disease, pulmonary fibrosis or interstitial pneumonia.\n17. Administration of a live attenuated vaccine within 10 days before inclusion and up to 6 months post-treatment.\n18. Patient refusal or inability to comply with study procedures.\n19. Inability to undergo follow-up for geographical, social, or psychological reasons.\n20. Participation in another clinical trial involving an investigational product within the 30 days prior to inclusion.\n21. Legal incapacity (patient under guardianship or guardianship).","75 Years",{"count":239,"type":22},162,[163],"The aim of this study is to evaluate the efficacy of sequential treatment (Gabrinox) comprising Gembrax regimen (Gemcitabine -Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) compared to folfirinox alone in patients treated in first metastatic line pancreatic cancer",[243],"Metastatic Pancreatic Cancer",[245,246],"pancreatic","cancer","2026-04-10",{"date":249,"type":33},"2026-04-15",{"date":251,"type":33},"2022-01-11",{"date":253,"type":22},"2028-06-30",{"name":39,"class":40},8,{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":264,"minAge":49,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":52,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":279},"100388799","predictive-toxicity-test-linked-to-radiotherapy-after-mastectomy-and-immediate-implant-reconstruction-100388799","NCT04342546","Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction","Prospective Evaluation of a Predictive Toxicity Test Post Radiotherapy After Mastectomy With Immediate Implant Reconstruction","PRETORIA","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients with histologically confirmed breast cancer with indication of mastectomy or surgery with mastectomy performed\n* Indication of wall chest radiation after mastectomy\n* Patient's agreement to receive or having had an immediate breast reconstruction by implant in one or two steps, with or without a dermal or synthetic matrix (depending on the habits of the center)\n* Performance Status 0-1\n* Consent signed before any study procedure\n* Patient geographically accessible for follow-up\n* Affiliated to the French national social security system\n\nExclusion Criteria:\n\n* Breast reconstruction with flap\n* Inflammatory breast cancer (cT4d)\n* Skin or parietal breast cancer (cT4 a, b or c)\n* Metastatic patients\n* Patients with bilateral breast cancer\n* History of homolateral breast cancer treated with radiotherapy\n* History of contralateral breast cancer\n* Pregnant or breastfeeding women\n* Legal incapacity or physical, psychological or mental status interfering with the patient's ability to sign the informed consent\n* Participation in an interventional clinical study or planned participation during study up to 12 months post-radiotherapy","MALE",{"count":266,"type":22},250,[54],"This study evaluates the capacity of the NovaGray RILA Breast® test to predict the toxicity linked to radiotherapy and the impact of implant breast reconstruction.",[81,270],"Capsular Contracture Associated With Breast Implant","2026-04-08",{"date":273,"type":33},"2026-04-13",{"date":275,"type":33},"2020-12-11",{"date":277,"type":22},"2031-12-10",{"name":39,"class":40},9,{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":75,"minAge":49,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":52,"phases":289,"briefSummary":290,"conditions":291,"keywords":295,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":4},"100633166","assessment-of-sexual-quality-of-life-following-local-treatment-radiotherapy-with-or-without-surgery-in-patients-with-hpv-positive-pelvic-cancer-a-descriptive-longitudinal-study-100633166","NCT07523152","Assessment of Sexual Quality of Life Following Local Treatment (Radiotherapy With or Without Surgery) in Patients With HPV-positive Pelvic Cancer: a Descriptive Longitudinal Study","SAPPHIRE","Inclusion Criteria:\n\n1. Women aged 18 or over.\n2. Sexually active patients, i.e. those who have been sexually active in the year prior to their cancer diagnosis.\n3. Patients being treated at the Montpellier Cancer Institute (ICM).\n4. Patient with pelvic squamous cell carcinoma (cervix, vagina, vulva or anus) and human papillomavirus (HPV+) infection\n5. Patient aware of her HPV status and how it is transmitted.\n6. Indicated for external radiotherapy\n7. Patient who has not received any oncological treatment prior to inclusion.\n8. Patient who has given verbal consent.\n\nExclusion Criteria:\n\n1. Patients receiving radiotherapy treatment outside the Montpellier Cancer Institute (ICM).\n2. Patients who are unwilling or unable to complete the study questionnaires.\n3. Patients under guardianship, curatorship or court protection,\n4. Patients for whom regular follow-up is impossible for psychological reasons,\n5. Patients who do not speak French.",{"count":288,"type":22},42,[54],"In patients with cancer associated with human papillomavirus (HPV), the physical effects of treatment, combined with the psychosexual impact linked to HPV status, can further impair the quality of sexual life.\n\nHowever, few studies have examined the specific effect of HPV status (or knowledge of status) on the recovery\u002Fquality of sexuality following radiotherapy.\n\nIt is against this backdrop that we propose a prospective longitudinal study specifically dedicated to investigating the sexual quality of life of women with HPV-positive pelvic cancer.\n\nThis type of study will enable better quantification and description of sexual dysfunction occurring after treatment, and assessment of the impact of HPV carriage, with the future aim of guiding new prevention and management strategies.",[292,293,294],"Pelvic Cancer","Anal Cancer","Vaginal Cancer",[296,297,298],"vaginal cancer","uterus cancer","anal canal cancer","2026-04-04",{"date":273,"type":33},{"date":302,"type":22},"2026-04-02",{"date":304,"type":22},"2027-10-31",{"name":39,"class":40},{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":18,"minAge":49,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":52,"phases":315,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":41},"100608239","feasibility-study-incorporating-music-therapy-to-optimise-the-smoking-cessation-process-coordinated-by-a-tobacco-addiction-nurse-in-smoking-patients-being-treated-for-cancer-100608239","NCT07198971","Feasibility Study Incorporating Music Therapy to Optimise the Smoking Cessation Process Coordinated by a Tobacco Addiction Nurse in Smoking Patients Being Treated for Cancer","TEMPOS","Inclusion Criteria:\n\n1. Patients over the age of 18\n2. Patients with tobacco-related or non-tobacco-related cancer (excluding blood cancer)\n3. Patients who smoke daily\n4. Patients wishing to begin a smoking cessation programme\n5. Patients with a prognosis of \\> 1 year\n6. Patients who have given their informed, written and express consent\n7. Patients affiliated with a French social security scheme\n\nExclusion Criteria:\n\n1. Patients with uncorrected hearing loss\n2. Patients with unstable psychiatric conditions\n3. Patients for whom regular follow-up is impossible for psychological, family, social or geographical reasons\n4. Patients under guardianship, curatorship or judicial protection",{"count":314,"type":22},26,[54],"The innovative nature of this project lies in the combination of three types of intervention: tobacco addiction treatment, music therapy and therapeutic education.\n\nThree disciplines that work together.\n\n1. Tobacco addiction treatment: reducing consumption, quitting,\n2. Music therapy: acting on emotions and reward circuits,\n3. Therapeutic education: promoting independent healthy practices. Patients learn to use the soundtrack independently to help them manage withdrawal symptoms caused by reducing or stopping tobacco consumption.\n\nIn this programme, patients play an active role on several levels:\n\n* working with the music therapist to create a personalised 'soundtrack';\n* identifying situations in which music can help them manage withdrawal symptoms;\n* using music independently in their everyday lives. The music therapy protocol will be proposed in this study, the soundtrack is co-created by the music therapist and the patient based on the patient's musical tastes and needs. The fact that the patient can use the musical tool independently also gives them significant leverage in their withdrawal process, allowing them to act on withdrawal symptoms and the main factors contributing to relapse.",[318],"Cancer (With or Without Metastasis)",[320,321,322],"Smoking cessation","music therapy","tobacco addiction treatment","2026-04-03",{"date":325,"type":33},"2026-04-09",{"date":327,"type":33},"2026-02-18",{"date":329,"type":22},"2026-12-31",{"name":39,"class":40},{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":18,"minAge":338,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":52,"phases":341,"briefSummary":342,"conditions":343,"keywords":345,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":41},"100550289","dynamics-of-motivational-factors-for-physical-activity-and-nutrition-in-oncogeriatrics-100550289","NCT06445140","Dynamics of Motivational Factors for Physical Activity and Nutrition in Oncogeriatrics","MONAGE","Inclusion Criteria:\n\n1. Patient aged 70 or over\n2. With cancer (solid tumors, all sites)\n3. G8 ≤ 14\n4. Inactive (patient not meeting recommended physical activity levels of 150 minutes per week at moderate intensity)\n5. Patient has given informed, written and express consent\n6. Patient affiliated to a French social security scheme.\n\nExclusion Criteria:\n\n1. Known presence of brain metastases\n2. Inability to participate in digital platform assessments or physical tests\n3. Inability to eat orally\n4. Contraindication or inability to engage in physical activity\n5. Patient unable to follow up regularly for psychological, family, numerical, social or geographical reasons\n6. Person deprived of liberty or under protective custody or guardianship.","70 Years",{"count":340,"type":22},55,[54],"Oncogeriatric: a collaboration between oncologists and geriatricians which aims to ensure that all elderly cancer patients receive treatment adapted to their condition, thanks to a multidisciplinary and multi-professional approach.\n\nThis project aims to gain a better understanding of the motivational determinants of PA and nutrition in elderly cancer patients.\n\nIt has a dual objective:\n\n1. to identify clusters\u002Fgroups in patients on the basis of daily motivational factors focusing on PA and nutrition\n2. on the basis of the results obtained in (1), to propose an interventional study based on the previously established clusters, in order to examine the effects of a behavioral intervention on patients' adherence to PA and nutrition, both agreed according to an individualized goal and defined in agreement with the patient and the multidisciplinary team, taking into account the recommendations.",[344],"Cancer",[346],"oncogeriatry","2026-03-10",{"date":349,"type":33},"2026-03-12",{"date":351,"type":33},"2024-06-18",{"date":353,"type":22},"2026-09-30",{"name":39,"class":40},{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":75,"minAge":49,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":52,"phases":364,"briefSummary":365,"conditions":366,"keywords":367,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":369,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":41},"100545508","personalization-of-breast-radiotherapy-according-to-loco-regional-recurrence-risk-and-toxicity-probability-100545508","NCT06382818","Personalization of Breast Radiotherapy According to Loco-regional Recurrence Risk and Toxicity Probability","PROBA","Inclusion Criteria:\n\nGeneral criteria (for all cohorts):\n\n1. Women ≥ 18 years old.\n2. Invasive breast cancer treated by conservative or radical surgery.\n3. Conservative breast cancer surgery or radical mastectomy.\n4. Indication of breast irradiation.\n5. Extension evaluation of disease will be proven negative (M0).\n6. Negative pregnancy test (blood or urine at the choice of investigator), to be carried out within 7 days of registration, for women of childbearing age only.\n7. Effective contraception for women of childbearing age\n8. Must be geographically accessible for follow-up.\n9. Written and dated informed consent.\n10. Affiliated to the French national social security system.\n\n    Cohort A and B:\n\n    \\- Low risk of recurrence (all of the criteria)\n\n    • pT1-T2\n    * SBR (Scarff Bloom et Richardson grade) grade ≤ 2 (low grade)\n    * ER+ and \u002F or PR+ (hormone-receptor positive)\n    * cN0\u002FpN-\n    * HER 2 -\n    * Ki67 ≤10%\n\n    pN- with T3-4 and grade 3 and internal tumor will be considered at high risk of recurrence and will be proposed node irradiation (and will be switched to COHORT C or D).\n\n    Cohort C and D:\n\n    \\- High risk of recurrence (pN+ and at least one of all) adapted from the UK PREDICT\n\n    • ER- and PR-\n\n    • HER2 amplified\n\n    • pT3-4\n\n    • SBR grade ≥ 3\n    * KI67 \\> 10%\n\n    Cohort A and C:\n    * Low risk of breast toxicities identified by the NovaGray RILA Breast® test\n\n    Cohort B and D:\n\n    \\- High risk of breast toxicities identified by the NovaGray RILA Breast® test\n\n    Exclusion Criteria:\n    * 1\\. Patients with distant metastases.\n\n2\\. Patients with breast DCIS (ductal carcinoma in situ) 3. Concomitant bilateral breast cancer 4. Previous breast radiotherapy 5. Patients with previous or concomitant other (not breast cancer) malignancy within the past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients who have had a previous other malignancy must have been disease free for at least five years.\n\n6\\. Patients with other non-malignant systemic diseases (cardiovascular, renal, hepatic, lung embolism, etc.) which would prevent prolonged follow-up.\n\n7\\. Patients known to be HIV positive (no specific tests are required to determine the eligibility).\n\n8\\. Patients known as hypersensitive to radiation 9. Patients treated with systemic investigational drugs during the present study (Observational cohorts are accepted if the collection of data does not interfere with the current trial) 10. Pregnant or breast-feeding women 11. Patient unable to comply with study obligations for geographic, social, or physical reasons, or who is unable to understand the purpose and procedures of the study 12. Person deprived of their liberty or under protective custody or guardianship",{"count":363,"type":22},854,[54],"Our objective is based on a personalized approach of adjuvant breast radiotherapy by selecting patients according to tumor recurrence and toxicity risk.",[81],[368],"Radiotherapy breast cancer",{"date":349,"type":33},{"date":371,"type":33},"2025-03-06",{"date":373,"type":22},"2038-03-06",{"name":39,"class":40},{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":75,"minAge":49,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":52,"phases":385,"briefSummary":386,"conditions":387,"keywords":388,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":391,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":41},"100520170","sahara-04--adaptive-radiotherapy-in-hypersensitive-patients-and-high-locoregional-risk-breast-cancer-with-ethos-technology-100520170","NCT06053086","SAHARA-04 : Adaptive Radiotherapy in Hypersensitive Patients and High Locoregional Risk Breast Cancer With ETHOS Technology","Adaptive Radiotherapy in Hypersensitive Patients and High Locoregional Risk Breast Cancer With ETHOS Technology","SAHARA-04","Inclusion Criteria:\n\n* Women ≥ 18 years old.\n* Conservative breast cancer surgery or radical mastectomy.\n* At least pN1 breast cancers, regardless breast cancer subtypes.\n* Tumor negative margins.\n* Indication of whole breast and node irradiation.\n* Extension evaluation of disease will be proven negative (M0).\n* Risk level of breast fibrosis identified by the centralized NovaGray RILA Breast® test\n* Must be geographically accessible for follow-up.\n* Written and dated informed consent.\n* Affiliated to the French national social security system.\n\nExclusion Criteria:\n\n* Patients with distant metastases.\n* Bilateral breast cancer (concomitant or prior) except in situ lesion, either ductal or lobular, of the contralateral breast.\n* Patients with previous or concomitant other (not breast cancer) malignancy within the past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients who have had a previous other malignancy must have been disease free for at least five years.\n* Patients with other non-malignant systemic diseases (cardiovascular, renal, hepatic, lung embolism, etc.) which would prevent prolonged follow-up.\n* Patients treated with systemic investigational drugs within the past 30 days (Observational cohorts are accepted if the collection of data does not interfere with the current trial)\n* Untreated hypothyroidism\n* Patients known to be HIV positive (no specific tests are required to determine the eligibility).\n* Patients known as hypersensitive to radiation (ATM Homozygote, p53-\u002F-,…)\n* Pregnant or breast-feeding women\n* Patient unable to comply with study obligations for geographic, social, or physical reasons, or who is unable to understand the purpose and procedures of the study\n* Person deprived of their liberty or under protective custody or guardianship.",{"count":384,"type":22},500,[54],"* Prospective, open-label, bi-center study, assessing the clinical outcomes of adaptive breast radiotherapy with ETHOS in hypersensitive patients.\n* Bi-centric with ETHOS center : ICM (Institut du Cancer de Montpellier) and ISC (Institut Sainte Catherine) Avignon\n* 500 patients will be included:\n* COHORTE A = Treatment ETHOS RT :46 evaluable patients with high risk of LRR and bf+ risk\n* COHORT B = Conventional IMRT : 454 others patients with high risk of LRR and bf- risk",[81],[389,191,246,390],"radiotherapy","ETHOS",{"date":349,"type":33},{"date":393,"type":33},"2025-03-01",{"date":395,"type":22},"2030-11-30",{"name":39,"class":40},{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":403,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":18,"minAge":49,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":407,"conditions":408,"keywords":412,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":66},"100626923","single-fraction-pulmonary-ablative-radiotherapy-outcomes-and-quality-of-life-workup-100626923","NCT07441941","Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup","Quality-of-Life Assessment Following Single-Fraction Stereotactic Radiotherapy (SF-SBRT) for Inoperable Primary and Oligometastatic Lung Tumor","SPARROW","Inclusion Criteria:\n\n* Age: ≥ 18 years\n* Patient receiving single-fraction stereotactic body radiation therapy (SBRT)\n* Stage T1-2 N0 M0 non-small cell lung cancer (NSCLC) (AJCC 6th edition) or oligometastatic lung tumor defined by ≤ 3 lung metastasis.\n* Inoperability: Tumor is inoperable or patient refuses surgery\n* Tumor size: ≤ 3 cm\n* Peripheral tumors: \\> 2 cm from proximal bronchial tree but ≥ 0.5 cm from the wall\n* Histologically proven or with evolution criteria (CT scan and PET scan)\n* ECOG performance status: 0-2\n* Ability to comply: Willingness and ability to comply with scheduled visits and other study procedures\n* Informed consent: Written informed consent obtained\n* Insurance: Patient is affiliated with a French health insurance plan\n\nExclusion Criteria:\n\n* Tumors invading the pleura or mediastinum.\n* Concurrent infectious pneumonia or pericarditis.\n* Prior radiotherapy to the treatment field.\n* Presence of neoadjuvant treatment for the present cancer.\n* Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results\n* Patients under guardianship, curatorship or safeguard of justice,\n* Pregnant or breast-feeding subjects\n* Concomitant participation or participation within the last 30 days in another clinical trial\n* Patient with an estimated life expectancy of less than 6 months.",{"count":406,"type":22},190,"Pulmonary tumors, whether primary or metastatic, represent a major challenge in oncology.\n\nPrimary lung cancers are responsible for nearly 37,000 deaths per year in France, highlighting the critical importance of their management. Moreover, secondary pulmonary lesions are present in 20% of solid cancers and show wide variability in prognosis. Oligometastatic disease (≤ 3 to 5 lesions) is associated with a better prognosis, justifying the development of local treatments for these lesions, particularly stereotactic radiotherapy.\n\nDuring the COVID-19 pandemic, single-fraction protocols (30-34 Gy) were implemented to limit patient exposure, showing outcomes equivalent to multi-fraction regimens for both primary and secondary lesions.\n\nHowever, the impact of these treatments on quality of life remains poorly documented-especially for non-small cell lung carcinoma-and needs to be further explored to optimize their integration into routine clinical practice.\n\nThe primary objective of this study is to assess the impact of single-fraction stereotactic body radiotherapy (SBRT) for pulmonary lesions on quality of life.\n\nTo this end, patients will complete a standardized French-language quality of life questionnaire, the EORTC QLQ-C30 and LC-29, before treatment and at 1 month (M1), 3 months (M3), 6 months (M6), 9 months (M9), and 12 months (M12) after treatment.\n\nThis validated, disease-specific questionnaire comprises 59 items: 30 assessing overall quality of life (QLQ-C30) and 29 addressing aspects related to lung cancer treatments (LC-29). It includes questions on respiratory symptoms, chest pain, fatigue, and the functional impact of the treatment.",[409,410,411],"Oligometastatic Lung Tumor","NSCLC (Non-small Cell Lung Cancer)","SBRT",[413,411,414],"Quality of life","Lung tumor","2026-02-26",{"date":417,"type":33},"2026-03-02",{"date":419,"type":33},"2026-01-14",{"date":421,"type":22},"2028-11-30",{"name":39,"class":40},{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":429,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":75,"minAge":49,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":52,"phases":433,"briefSummary":434,"conditions":435,"keywords":436,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":446,"locationsCount":202},"100536494","prevention-of-postoperative-complications-by-negative-pressure-therapy-after-complex-breast-cancer-surgery-100536494","NCT06265558","Prevention of Postoperative Complications by Negative Pressure Therapy After Complex Breast Cancer Surgery","Prevention of Postoperative Complications by Negative Pressure Therapy After Complex Breast Cancer Surgery: a Prospective Randomized Controlled Trial","TPN-SEIN","Inclusion Criteria:\n\n1. Female ≥ 18 years\n2. Patient with unilateral invasive or in situ breast carcinoma\n3. Patient with or without neoadjuvant treatment\n4. Patient presenting an indication for complex breast surgery by mastectomy with immediate breast reconstruction by implant or oncoplasty by T-shaped mammoplasty.\n5. Patient presenting at least one of the following risk factors for scarring disorders:\n\n   * Obesity with Body Mass Index BMI ≥ 30 and\u002For Cup size ≥ E\n   * Active smoking or smoking cessation for less than one month\n   * Diabetes\n   * History of homolateral breast radiotherapy\n   * Long-term corticosteroid therapy\n6. Patient to have signed informed consent prior to study entry\n7. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.\n8. Patient affiliated with a health insurance plan.\n\nExclusion Criteria:\n\n1. Legal incapacity or limited legal capacity. Medical or psychological conditions preventing the patient from completing the study or signing the consent form.\n2. Pregnant or breast-feeding patient as determined in medical records as part of standard patients care and follow-up\n3. Patient under guardianship or safeguard of justice\n4. Patient participating in an interventional study with the objective of wound healing\n5. Any concurrent or planned surgical procedure on the contralateral breast",{"count":432,"type":22},254,[54],"There is little scientific data concerning the use of negative pressure therapy after immediate breast reconstruction.\n\nThat strategy of treatment-reconstruction has expanded increasingly since the last years.\n\nThe current literature reports only 3 studies on the use of preventive negative pressure therapy in oncologic breast surgery.\n\nMoreover, all three are retrospective, case-control studies with serious limitations.\n\nThe largest published series reports a reduction in the overall complication rate from 15.9% to 8.5%, and a significant reduction in several criteria: infection, scar dehiscence and necrosis. However, the study presents significant biases, with non-comparable populations in terms of comorbidities, surgical procedure performed, inclusion periods (and therefore experience in performing oncological surgery).\n\nThere was also a high probability of under-assessment or postponement of post-operative complications, which is typical of published retrospective surgical studies.\n\nThe published results therefore strongly encourage further investigation of negative pressure therapy in oncological breast surgery.",[81],[437,438,439],"Pressure negative therapy","Breast surgery","Mastectomy","2026-02-03",{"date":442,"type":33},"2026-02-05",{"date":444,"type":33},"2025-04-15",{"date":37,"type":22},{"name":39,"class":40},{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":453,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":18,"minAge":49,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":52,"phases":457,"briefSummary":459,"conditions":460,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":463,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":467,"locationsCount":468},"100420005","phase-2-study-evaluating-the-tailored-management-of-locally-advanced-rectal-carcinoma-100420005","NCT04749108","Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma","Multicentric Phase II-III Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma After a Favorable Response to Induction Chemotherapy","GRECCAR14","INCLUSION CRITERIA FOR SCREENING\n\n1. Written consent,\n2. Patient who receive Folfirinox,\n3. Patient aged over 18 years old,\n4. World Health Organization (WHO) performance status ≥ 1,\n5. Histologically confirmed diagnosis of adenocarcinoma of the rectum,\n6. Distal part of the tumor from 1 to 12 cm from the upper part of the levator ani (dynamic rectal examination),\n7. No unequivocal evidence on CT-Scan of established metastatic disease,\n8. MRI evaluation of the locally advanced tumor before neoadjuvant chemotherapy:\n\n   1. Predictive CRM \\\u003C 2 mm\n   2. Or T3c-d (extending ≥ 5 mm beyond the muscularis propria) with extra mural venous invasion (EMVI)\n   3. Or T4a-b (except bone and sphincteric invasion).\n\nNON INCLUSION CRITERIA FOR SCREENING\n\n1. Non measurable rectal tumor or not assessed by MRI before inclusion,\n2. Ultra-low rectal tumor at diagnosis which imposes radiotherapy administration (inferior tumor pole less than 1 cm from the upper part of the levator ani).\n3. Active cardiac disease including any of the following: a. Congestive heart failure ≥ New York Heart Association (NYHA) class 2 (appendix 4), b. Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months), c. Myocardial infarction less than 6 months before first dose of treatment, d. Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted),\n4. Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years prior to study inclusion, except for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors \\[Ta (non invasive tumor), Tis (carcinoma in situ) and T1 (lamina propria invasion)\\],\n5. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before start of treatment.\n\nINCLUSION CRITERIA FOR EXPERIMENTAL TREATMENT\n\n1. WHO performance status 0-1,\n2. Patient with tumoral regression ≥ 60% and CRM ≥ 1mm,\n3. No unequivocal evidence on CT-Scan of established metastatic disease,\n4. General condition considered suitable for radical pelvic surgery and a systemic therapy with Capecitabine\n5. Adequate hematologic, hepatic, renal and ionogram function assessed within 7 days prior to study treatment a. Platelet count ≥ 100,000\u002Fmm3; Hemoglobin (Hb) ≥ 9 g\u002FdL; Absolute neutrophil count (ANC) ≥ 1,500\u002F mm3 b. Total bilirubin ≤ 1.5 x Upper Limit Normal (ULN), Alkaline phosphatases ≤ 3 x ULN and ASpartate aminoTransferase (AST) and ALanine aminoTransferase (ALT) ≤ 3 x ULN, c. Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 50 ml\u002Fmin according to Modification of Diet in Renal Disease (MDRD),\n6. For women of reproductive potential, negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test obtained within 7 days before the start of study treatment. Women not of reproductive potential are female patients who are postmenopausal or permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy),\n7. For women of childbearing potential and men, agreement to use an adequate contraception for the duration of study participation and up to 6 months following completion of therapy. Females of childbearing potential who are sexually active with a non-sterilized male partner must use 2 methods, of effective contraception. The investigator or a designated associate is requested to advise the patient on how to achieve an adequate birth control. Adequate contraception is defined in the study as any medically recommended method (or combination of methods) as per standard of care,\n8. No evidence of chronic or acute ischemic heart disease,\n9. Willing to participate to the study, and able to give informed consent and to comply with the treatment and follow-up schedules,\n10. Affiliation to the French Social Security System.\n\nNON-INCLUSION CRITERIA FOR EXPERIMENTAL TREATMENT\n\n1. Patient with a history of pelvic radiotherapy,\n2. Contraindication to chemotherapy and\u002For radiotherapy,\n3. Complete or partial Dihydropyrimidine deshydrogenase (DPD) deficiency (uracilemia ≥ 16 ng\u002FmL),\n4. Any infection that could jeopardize treatment administration,\n5. Any other serious concomitant disease or disorder that may interfere with the patient's participation in the study and safety during the study (e.g., severe liver, heart, kidney, lung, metabolic, or psychiatric disorders),\n6. History of inflammatory bowel disease,\n7. Patients with a history of pulmonary fibrosis or interstitial pneumonia,\n8. Patients using antivitamin K (Coumadin etc…) but it's possible to substitute the antivitamin K treatment with low molecular weight heparins (LMWHs) before starting chemotherapy,\n9. Known hypersensitivity to Capecitabine drug, study drug classes, or any constituent of the products,\n10. Patient who received live attenuated vaccine within 10 days of inclusion,\n11. Pregnant or breastfeeding woman. If a patient is of childbearing age, she must have a negative pregnancy test (serum β-hCG) documented 72 hours prior to inclusion,\n12. Patient treated with an investigational drug within the last 30 days,\n13. Patient under curatorship or guardianship or safeguard justice,\n14. Inability to submit to medical monitoring of the trial for geographical, social or psychological reasons.",{"count":456,"type":22},1075,[163,458],"PHASE3","Locally advanced rectal carcinoma raise the issue of both the oncological control, local and general, and the therapeutic morbidity. Surgery alone can cure only one out of two patients, radiochemotherapy improves the local control but the metastatic risk remains about 30% with enhanced postoperative morbidity and poor functional results. The tumor response to preoperative treatment is the major prognostic factor which revealed the aggressiveness of the tumor. To this day, there are no biologic predictive markers for tumor response.\n\nThe purpose of this trial is to tailor the management according to the early tumoral response after short and intensive induction chemotherapy. MRI volumetric tumor response will be used to distinguish between good responders and bad responders.\n\n\"Very good\" responders will be randomized to either immediate surgery or radiochemotherapy followed by surgery (Standard arm: Cap 50).",[461,462],"Locally Advanced Malignant Neoplasm","Rectal Carcinoma",{"date":442,"type":33},{"date":465,"type":33},"2021-11-26",{"date":89,"type":22},{"name":39,"class":40},30,{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":75,"minAge":49,"maxAge":477,"enrollmentInfo":478,"targetDuration":4,"studyType":52,"phases":480,"briefSummary":481,"conditions":482,"keywords":484,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":41},"100398527","diet-modification-in-patients-with-luminal-early-breast-cancer-candidate-for-primary-surgery-100398527","NCT04469296","Diet Modification in pAtients With Luminal Early Breast Cancer Candidate for Primary Surgery","Trial Studying the Feasibility of a Diet Modification in pAtients With Luminal Early Breast Cancer Candidate for Primary Surgery","MACS","Inclusion Criteria:\n\n* Women 18 to 80 years old\n* Invasive breast carcinoma, non-metastatic, stage I to III, pathologically proven, ER and\u002For PR positive, HER2 negative (luminal)\n* No treatment yet for the current breast cancer\n* Candidate for primary surgery\n* Body mass index (BMI) between 18.5 and 30 for women up to 70 years old and between 21 and 30 for women between 70 and 80 years old.\n* For patient ≥ 70 years, score of the Oncodage G8 questionnaire \\> 14 (if score ≤ 14, consultation with an oncogeriatrician required to validate the possibility of following a diet\n* No addiction (alcohol, tobacco, drug, electronic cigarette) that modifies the metabolism (alcohol : ≤ 2 glasses\u002Fd or ≤10 glasses\u002Fweek ; tobacco : only occasional or stopped for ≥ 6 months)\n* Performance status 0-1\n* Fasting blood test :\n\nBlood cell counts : Neutrophils \\> 1000\u002FµL, Platelets \\> 100 000\u002FµL, Hb \\> 11g\u002FdL Hepatic biology: GOT, GPT, GGT, Phosphatases alcalines \\\u003C 2x normal value Renal function : clearance \\> 60 mL \u002Fmin Lipid profile : Total cholesterol \\\u003C 1.5 x normal value, HDL\\>0.35g\u002FL, LDL \\\u003C 2.2 g\u002FL (\\\u003C5.7 mml\u002FL), Triglycerides \\\u003C 1.5 x normal value Fasting blood glucose \\\u003C 1.26 g\u002Fl Measurement of electrolytes: Potassium, Sodium, Calcium, Magnesium (according to normal laboratory values)\n\n* ECG with a QTc interval ≤ 450 msec\n* Patient able to understand, participate and give a written consent for participation to the study\n\nExclusion Criteria:\n\n* Metabolic disease or other disease impairing the metabolism analysis\n* High level athlete\n* Unintentional weight loss ≥ 5% during the last month, or 10% during the last 6 months or compared to usual weight\n* Unjustified dietary supplement (not justified by a measured deficiency) during the last month\n* Restricted of unbalanced diet (vegan diet, restricted hypocaloric, hyper or hypo protein…) during the last month\n* Practice of fasting during the last 3 months\n* Corticoids that can't be stopped or not stopped for 2 weeks\n* Mellitus diabetes (with or without insulin)\n* Hypercholesterolemia requiring a treatment\n* Invasive lobular carcinoma\n* Pregnant or breast-feeding women\n* Participation to another study with an investigational treatment during the last 30 days\n* Individuals under the protection of a conservator\n* Unaffiliated patient to Social Protection System.","80 Years",{"count":479,"type":22},75,[54],"to analyze the feasibility for patients with early luminal breast cancer to be compliant with a diet modification - ketogenic or proteins restricted diet - during 9 +\u002F- 1 days, before breast cancer surgery.\n\nIt's a Pilot study, monocentric, randomized",[81,483],"Surgery",[485],"dietary survey,","2026-01-15",{"date":488,"type":33},"2026-01-16",{"date":490,"type":33},"2021-05-18",{"date":492,"type":22},"2026-12",{"name":39,"class":40},{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":500,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":18,"minAge":49,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":52,"phases":504,"briefSummary":505,"conditions":506,"keywords":510,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":515,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":519,"locationsCount":41},"100364414","impact-of-cardiac-coherence-on-anxiety-in-patients-operated-on-for-a-peritoneal-carcinosis-100364414","NCT04024917","Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis","Implementation of a Cardiac Coherence Program to Reduce Anxiety in Patients With Peritoneal Carcinosis Treated by Surgery: Randomized Pilot Study","COCOON","Inclusion Criteria:\n\n1. Age over 18 years\n2. Patients with peritoneal carcinosis awaiting cytoreductive surgery\n3. Patients who scored strictly above 3 on the visual analogue anxiety scale and\u002For the psychological distress scale\n4. Patients with sufficient command of the French language\n5. Patient affiliated to a French social security system\n6. Patient hospitalized at the Institute of cancer of Montpellier the day before his cytoreductive surgery (at T1 = D-1)\n7. Signing of informed consent before any specific trial procedure\n\nExclusion Criteria:\n\n1. Patients who already have daily practice of cardiac coherence\n2. Presence of proven psychiatric disorders (e.g., mental retardation, psychotic disorders, learning disabilities, attention deficit\u002Fhyperactivity, bipolar disorder, etc.) other than mood disorders that are reactive to the disease experience, or receiving psychotic treatment that may impair thinking, judgment or discernment\n3. Physical or sensory inability to respond to questionnaires\n4. Patients who have had a heart transplant or bypass surgery in the Year before surgery\n5. Patient with a history of uncontrolled neurological pathology within the last 6 months before inclusion in the trial\n6. Patients with a history of psychoactive substance dependence (excluding smoking) in the last 6 months before inclusion in the trial\n7. Patients with brain metastases\n8. Known natural bradycardia 50 beats per minute\n9. Beta-blocker intake in progress\n10. Ongoing cardiac arrhythmias\n11. Known severe heart failure with ventricular ejection fraction strictly Below 40 %\n12. Chronic uncontrolled pain and making it difficult to practice the technique\n13. Patient with chronic obstructive pulmonary disease\n14. Legal incapacity (patient under guardianship or curatorship)",{"count":503,"type":22},60,[54],"The investigator proposes to use the cardiac coherence technique to diminish anxiety before the surgery of a peritoneal carcinosis of colon or stomach or ovary and pseudomyxoma or peritoneal mesothelioma.",[507,508,509],"Peritoneal Carcinomatosis","Pseudomyxoma Peritonei","Mesothelioma Peritoneum",[511,512,513,514],"Colon","Rectum","Stomach","Ovary",{"date":488,"type":33},{"date":517,"type":33},"2021-09-21",{"date":492,"type":22},{"name":39,"class":40},{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":18,"minAge":49,"maxAge":4,"enrollmentInfo":528,"targetDuration":4,"studyType":52,"phases":530,"briefSummary":531,"conditions":532,"keywords":534,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":542,"leadSponsor":544,"locationsCount":545},"100596291","evaluation-of-the-clinical-utility-of-online-adaptive-radiotherapy-in-bladder-cancer-bladapt-getug-v11-100596291","NCT07043543","Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)","Randomized Open Phase II Multienter Study Evaluating the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer","BLADAPT","Inclusion Criteria:\n\n* Histologically proven muscle-infiltrating bladder cancer (de novo MIBC or after a history of non-muscle-invasive bladder cancer) or patients with initial high-grade T1 tumor showing Ta or T1 recurrence, or those with high-grade T1 after a course of intravesical biological therapy or chemotherapy;\n* Age ≥ 18 years;\n* Urothelial carcinoma (transitional cell carcinoma of the bladder, micropapillary, microcystic with trophoblastic differenciation) and squamous cell histological types are allowed;\n* Stage T1-T4aN0M0\n* TransUrethral Resection of Bladder Tumor (TURBT) and Position Emission Tomography- scanner and X-ray Computed Tomography (PET-CT) or Computed Tomography scan of thorax\u002Fabdomen\u002Fpelvis (without carcinological anomaly) within 8 weeks prior to the start of radiation therapy (if TURBT was performed more than 6 weeks before the inclusion visit, a new TURBT or, at least, a cystoscopy showing no progression, no residual tumour or regrowth must be done);\n* Suitable for radiotherapy;\n* Eastern Cooperative Oncology Group\u002FWorld Human Organisation (ECOG\u002FWHO) performance status from 0 to 2\n* Negative pregnancy test (blood or urine), for women of childbearing age only;\n* If the patient is sexually active, he\u002Fshe must agree to use contraception deemed adequate and appropriate by the investigator throughout the period of study drug administration and 6 months after the end of treatment for both men and women.\n* Affiliation to the French Social Security System;\n* Dated, written and signed Informed consent\n\nExclusion Criteria:\n\n* Prior pelvic radiation therapy;\n* Patients with previous or concomitant other malignancy within the past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients who have had a previous other malignancy must have been disease free for at least five years;\n* Presence of endopenic stent;\n* Inability to comply with the protocol;\n* Grade 1 or greater baseline diarrhea;\n* Uncontrolled inflammatory bowel disease (ulcerative colitis or Crohn's disease);\n* Uncontrolled immune or cardiac or pulmonary disease;\n* Patients whose regular follow-up is impossible for psychological, family, social or geographical reasons;\n* Legal incapacity or physical, psychological or mental status interfering with the patient's ability to sign the informed consent or to terminate the study;\n* Pregnant or breast-feeding subjects",{"count":529,"type":22},120,[54],"Trimodal therapy (TMT) consisting of transurethral resection of bladder tumors followed by radiotherapy and chemotherapy is a therapeutic alternative in patients with Muscle-Infiltrating Bladder Cancer who are inoperable or refuse surgery. One of the main challenges of TMT is the planning and delivery of radiation therapy. Indeed, the bladder is a mobile hollow organ subject to repletion, with variations in size and shape during and between radiotherapy sessions. Standard radiotherapy techniques require large planning target volume margins around the bladder, which can be responsible for irradiation of a large volume of large and small bowel with grade 2 and 3 toxicities.\n\nAdaptive radiotherapy allows for the generation of a treatment fraction personalized to a patient's anatomical modification with margin reduction and improves the dosimetric quality of the delivered plans.\n\nThe hypothesis is that this improvement results in radiation-induced toxicity improvement.",[533],"Bladder Cancer",[535,536,537],"Adaptive radiotherapy","standard radiotherapy","Tri-Modal therapy","2025-12-12",{"date":540,"type":33},"2025-12-15",{"date":486,"type":22},{"date":543,"type":22},"2033-09-30",{"name":39,"class":40},11,{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":552,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":18,"minAge":49,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":52,"phases":556,"briefSummary":557,"conditions":558,"keywords":560,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":255},"100552060","efficacy-of-a-mixed-distancial-neuropsychological-rehabilitation-program-in-patients-with-grade-2-or-3-diffuse-glioma-100552060","NCT06468176","Efficacy of a Mixed Distancial Neuropsychological Rehabilitation Program in Patients With Grade 2 or 3 Diffuse Glioma","Efficacy of a Mixed Distancial Neuropsychological Rehabilitation Program in Patients With Grade 2 or 3 Diffuse Glioma : a Randomized Controlled Trial","FREEDOME","Inclusion Criteria:\n\n* Age ≥18 years old, no age limit;\n* Histo-molecular diagnosis of grade 2 or 3 diffuse glioma according to World Health Organization (WHO) Classification 2016, regardless of oncological treatments previously received;\n* Patient in satisfactory general condition for the study, defined by a WHO performance index ≤ 2 (ECOG-Performance Status (PS) ≤ 2);\n* Neurosurgical excision (excluding biopsy) performed ≥ 12 months previously;\n* In the case of oncological treatment, patient who has completed his sessions (radiotherapy, chemotherapy) for ≥ 6 months;\n* Patient presenting a cognitive complaint defined as a response rated at least \"Fairly\" to at least one of the 2 items (n°20 and 25) assessing cognitive complaint in the EORTC QLQ-C30 questionnaire (i.e., defined as a score on the \"Cognitive Functioning\" scale ≤ 66.67);\n* Fluent in French;\n* Affiliation to the French Social Security System;\n* Possible regular use of a digital tool with Internet access;\n* Signature of informed consent prior to any study procedure.\n\nExclusion Criteria:\n\n* Visual or auditory deficit not corrected to normal and\u002For preventing use of computer tools (i.e., homonymous lateral hemianopia is not a criterion for non-inclusion) ;\n* Concurrent participation in a study with cognition as primary endpoint (e.g., \"POLCA\", \" POLO \" clinical trials) ;\n* Legal incapacity or physical, psychological, social or geographical conditions preventing the patient from signing the consent form or completing the study ;\n* Unstable or uncontrolled psychiatric syndrome (i.e., psychotropic treatments are not a criterion for non-inclusion if doses are stable) ;\n* Known severe cognitive impairment (e.g., neurodegenerative disease, sequelae of head trauma, etc.) or defined by a score ≤ 20 on the MoCA test or impacting the ability to use digital tools at home ;\n* Oncological treatment (radiotherapy and\u002For chemotherapy and\u002For surgery) planned within 4 months of inclusion. Targeted anti-Isocitrate DeHydrogenase (IDH) therapies are authorized.",{"count":555,"type":22},187,[54],"Diffuse low-grade glioma are rare brain tumors affecting young subjects (median age at diagnosis 38 years for grade 2 and 49 years for grade 3). Cognitive symptoms are common in these patients, including memory, attention and executive function disorders. These disorders may have a deleterious impact on patients' professional, family and social lives, and have a negative impact on their quality of life. The benefits of cognitive rehabilitation have been demonstrated in other neurological pathologies. Furthermore, due to limited access to rehabilitation by neuropsychologists, some studies have evaluated the impact of digital cognitive rehabilitation programs. However, it cannot replace human support.",[559],"Glioma, Malignant",[561,562,563,564],"Oncology","Neurologic Disorder","Neuropsychological rehabilitation","Diffuse Glioma",{"date":566,"type":33},"2025-12-19",{"date":568,"type":33},"2024-07-05",{"date":570,"type":22},"2027-12-15",{"name":39,"class":40},{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":578,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":18,"minAge":49,"maxAge":237,"enrollmentInfo":580,"targetDuration":4,"studyType":52,"phases":582,"briefSummary":583,"conditions":584,"keywords":586,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":279},"100406325","phase-2-sequential-treatment-with-gembrax-and-then-folfirinox-followed-by-stereotactic-mri-guided-radiotherapy-in-patients-with-locally-advanced-pancreatic-cancer-100406325","NCT04570943","Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","Phase II Study to Assess the Interest of a Sequential Treatment With Gemcitabine\u002FNab-paclitaxel (GEMBRAX) and Then FOLFIRINOX Followed by Stereotactic Magnetic Resonance-guided Adaptive Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","GABRINOX-ART","Inclusion Criteria:\n\n1. Patient aged from 18 to 75 years at the date of signature of the consent form\n2. Histologically or cytologically proven pancreatic adenocarcinoma\n3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1\n4. Non-resectable tumour according to the National Comprehensive Cancer Network (NCCN) 1.2015 recommendations after external review of imaging data by multidisciplinary experts.\n5. Non-metastatic cancer confirmed by thorax-abdomen-pelvis computerized tomography (CT) scan and liver MRI\n6. SMART feasibility confirmed by centralized review\n7. Uracilemia \\\u003C 16 ng\u002Fml\n8. Hematological assessment within 14 days before inclusion, defined by:\n\n   * Neutrophils ≥ 2 000\u002Fmm3 (2 × 109\u002FL);\n   * Platelets ≥ 100 000\u002Fmm3 (100 × 109\u002FL);\n   * Hemoglobin ≥ 9 g\u002Fdl\n9. Liver function (within 14 days before inclusion) defined by:\n\n   * ASpartate Transaminase (AST) and ALanine Transaminase (ALT) ≤ 2.5 x Upper Limit of Normal (ULN);\n   * Total bilirubin ≤ 1.5 x ULN. Patients with a metallic biliary prosthesis due to biliary obstruction caused by the cancer may be included, if: a CT scan with injection of contrast medium and thin pancreas sections was performed before placing the biliary prosthesis, the bilirubin level after prosthesis fitting decreased to ≤20 mg\u002FL (≤34 μmol\u002FL), and in the absence of cholangitis.\n10. Creatininaemia within the reference limits, or calculated clearance ≥50 ml\u002Fmin for patients with a serum creatinine value above or below the reference values (clearance calculated using the Chronic Kidney Disease EPIdemiology collaboration (CKDEPI formula).\n11. Serum calcium AND magnesium AND potassium ≥ Lower Limit Normal (LLN and ≤ 1.2 x Upper Limit Normal (ULN)\n12. Cancer Antigen (CA 19.9) \\\u003C500 IU\u002FmL (without cholestasis). Patients with CA 19.9 between 500 IU\u002FmL and 1000 IU\u002FmL can be included if the Positron Emission Tomography (PET) scan and peritoneal MRI (optional) do not detect any distant fixation, indicative of metastasis. Patients with CA 19.9 ≥ 1000 IU\u002FmL cannot be included.\n13. Sexually active patients must use a contraceptive method considered adequate and suitable by the investigator during the entire period of administration of the study treatment and up to 6 months after the treatment end, for female and male patients.\n14. Signature of the consent form before any study-specific procedure.\n15. Covered by the French health insurance.\n\nExclusion Criteria:\n\n1. Any previous treatment for pancreatic cancer (e.g. chemotherapy, radiotherapy, surgery, targeted therapy, experimental therapy)\n2. Gilbert's syndrome or homozygous Uridine DiPhosphate Glucuronosyl Transferase 1 A1 (UGT1A1 \\* 28)\n3. Other concomitant cancer or history of cancer, except for treated in situ cancer of the cervix , basal cell or squamous cell carcinoma, superficial bladder tumour (Ta, Tis, and T1), or good-prognosis tumour cured without chemotherapy and without signs of disease in the 3 years before inclusion\n4. Prior radiotherapy likely to overlap with the planned study radiotherapy area (e.g. previous abdominal irradiation).\n5. Patients with high cardiovascular risk, including, but not limited to, coronary stent or myocardial infarction in the past 6 months.\n6. Peripheral neuropathy ≥ grade 2\n7. ECG with QTcorrected (QTc) interval longer than 450 ms for men and longer than 470 ms for women\n8. Contraindication to MRI and MRI-guided radiotherapy\n9. History of chronic inflammatory disease of the colon or rectum\n10. Any other concomitant and not controlled serious illness or disturbance that may interfere with the patient's participation in the study and safety during the study (e.g. severe liver, kidney, lung, metabolic, or psychiatric disorder)\n11. Intolerance or allergy to one of the study drugs (gemcitabine, Nab-paclitaxel, oxaliplatin, irinotecan, 5-FU) or to one of their excipients (e.g. fructose) listed in the Contraindications or Warnings sections and Special precautions of the Summary of Product Characteristics (SmPC) or prescription information\n12. Legal incapacity (patient under guardianship or wardship)\n13. Pregnant or breastfeeding woman. Fertile women must have a negative pregnancy test (serum β-hCG) performed 72 hours before inclusion\n14. Patient using vitamin K antagonists (Coumadin…) (possible modification of the treatment before inclusion)\n15. Active and uncontrolled bacterial or fungal infection that requires systemic treatment.\n16. Know active HIV infection\n17. History of peripheral arterial disease (e.g. lameness, Buerger's disease).\n18. Patient who received a attenuated live vaccine in the 10 days before inclusion\n19. Patient with history of pulmonary fibrosis or interstitial pneumonia.\n20. Inability to attend the follow-up visits due to geographic, social or mental reasons.\n21. Participation in another clinical study with a research product during the last 30 days before inclusion.",{"count":581,"type":22},103,[163],"The aim of this study is to demonstrate the efficacy of intensified and sequential chemotherapy (Gabrinox) comprising Gembrax regimen (Gemcitabine-Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) in patients with locally advanced pancreatic adenocarcinoma.\n\nThe study will also demonstrate the feasibility of combining this intensified chemotherapy with MRI-guided stereotactic radiotherapy in non-progressive patients after the chemotherapy by Gabrinox regimen.",[585],"Locally Advanced Pancreatic Adenocarcinoma",[587,246],"Pancreatic","2025-11-28",{"date":590,"type":33},"2025-12-05",{"date":592,"type":33},"2021-06-16",{"date":594,"type":22},"2030-06",{"name":39,"class":40},{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":600,"acronym":601,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":75,"minAge":49,"maxAge":4,"enrollmentInfo":603,"targetDuration":4,"studyType":52,"phases":604,"briefSummary":605,"conditions":606,"keywords":607,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":41},"100542827","study-of-sexual-quality-of-life-in-women-with-breast-cancer-who-had-multidisciplinary-management-with-photobiomodulation-for-genitourinary-syndrome-of-the-menopause-100542827","NCT06347926","Study of Sexual Quality of Life in Women With Breast Cancer Who Had Multidisciplinary Management With Photobiomodulation for Genitourinary Syndrome of the Menopause","EVABIOSEIN","Inclusion Criteria:\n\n1. Woman ≥ 18,\n2. Diagnosis of breast cancer regardless of tumor biology or stage (localized or metastatic),\n3. Patient with persistent menopause genito-urinary symptoms after a minimum of 3 months of local treatment with vaginal moisturizers,\n4. Patient eligible for photobiomodulation as 2nd-line treatment for menopausal genitourinary syndrome as part of routine care.\n\nExclusion Criteria:\n\n1. Patient who have already undergone or are undergoing a 2nd-line treatment for menopause genito-urinary symptoms (photobiomodulation, laser, intra-vaginal injection of hyaluronic acid, etc.),\n2. Patient with psychic or cognitive impairment, or not sufficiently fluent in French to be able to fill in the quality of life questionnaires.",{"count":7,"type":22},[54],"The treatment of breast cancer as well as the disease are responsible for genito-urinary symptoms that can persist over time and impair quality of life. Given the improved prognosis of breast cancer, more and more patients are confronted with specific post-cancer issues, and the care has become a major health challenge.\n\nSexual health is a crucial component of well-being and overall quality of life. Vaginal dryness and dyspareunia are symptoms frequently found in patients treated for breast cancer, with chemotherapy and hormone therapy as risk factors. However, the treatment of sexual disorders remains underdeveloped in France.\n\nVaginal dryness is part of a broader syndrome known as genitourinary syndrome of menopause (GSM), or vulvovaginal atrophy, which may combine vulvovaginal (dryness, irritation, burning), sexual (dyspareunia) and urinary (infections, pollakiuria, urgency) symptoms secondary to hypoestrogenemia, exacerbated by breast cancer treatments. Since hormonal treatments are contraindicated, the first-line treatment for GSM in patients treated for breast cancer is the application of non-hormonal trophic treatments (regular vaginal moisturizers, lubricants during intercourse). However, these treatments are often insufficient to provide effective relief. There is therefore growing interest in the development of second-line treatments for GSM : intra-vaginal hyaluronic acid injections, laser, photobiomodulation (PBM), etc. PBM using Light Emitting Diodes (LED) has been proposed as an alternative treatment for genitourinary syndrome of the menopause. The tissues are exposed to light sources in the visible spectrum, inducing non-thermal, non-cytotoxic biological effects that improve vaginal tissue trophicity.\n\nIn line with previous studies of sexual quality of life carried out at the center, and in the context of the recent establishment of our multidisciplinary network for the 2nd-line treatment of genitourinary menopausal syndrome with Photobiomodulation, we would like to carry out a descriptive study of the sexual QoL of patients undergoing treatment for breast cancer and benefiting from this oncosexological support.",[81],[608,609,610,611,612],"Sexual troubles","Irritation","Dyspareunia","Vaginal dryness","Photobiomodulation","2025-11-14",{"date":615,"type":33},"2025-11-18",{"date":617,"type":33},"2025-03-13",{"date":619,"type":22},"2027-12",{"name":39,"class":40},""]